PDCD1 and cancer: Immune checkpoint inhibitors (ICIs) including programmed cell death 1 (PD‐1) inhibitors and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) inhibitors are novel targeted cancer therapies regarded as having less toxicity than chemotherapy agents.